Table 3. Association of UCP polymorphisms with pCAD.

	N (%)			MAF	Model	OR (95% CI)	Pc
UCP2 A55V	C/C	C/T	T/T
Control	191 (25.0)	394 (51.7)	178 (23.3)	0.491	Dominant	0.095 (0.76-1.19)	0.682
(N= 763)
pCAD	256 (27.1)	459 (48.7)	228 (24.2)	0.485	Recessive	1.15 (0.92-1.43)	0.193
(N= 943)					Additive	1.09 (0.88-1.35)	0.114
UCP2 -866	G/G	G/A	A/A
Control	222 (29.1)	377 (49.4)	164 (21.5)	0.461	Dominant	0.82 (0.65-1.03)	0.098
(N= 763)
pCAD	211 (22.2)	501 (52.8)	236 (24.9)	0.513	Recessive	1.43 (1.15-1.78)	0.003
(N= 943)					Additive	0.68 (0.53-0.85)	< 0.001
UCP3 -55	C/C	C/T	T/T
Control	552 (72.3)	192 (25.2)	19 (2.5)	0.150	Dominant	1.29 (0.67-2.49)	0.432
(N= 763)
pCAD	708 (74.7)	219 (23.3)	18 (1.9)	0.134	Recessive	1.14 (0.91-1.41)	0.229
(N= 943)					Additive	1.15 (0.93-1.42)	0.362

pCAD: premature coronary artery disease. MAF: Minor Allele Frequency. The models were adjusted by age, gender, BMI, and HDL-C.

Bonferroni correction was made multiplying by 3 comparisons (Pc). Significant p values are in bold.